Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635150 | 1.00 | CES2 (0.45) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL14607861 | 1.00 | CES2 (0.45) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL29729972 | 1.00 | CES2 (0.45) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL29649098 | 1.00 | CES2 (0.45) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL18921489 | 0.96 | CES2 (0.42) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL25159745 | 0.85 | CES2 (0.47) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL7786410 | 0.85 | CES2 (0.47) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL3175425 | 0.83 | CES2 (0.46) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL13849940 | 0.81 | CES2 (0.45) | CES2CES1GRIN2BHDAC4HDAC7 | |
| SCHEMBL14402601 | 0.81 | CES2 (0.45) | CES2CES1GRIN2BHDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI, INC. (KR) | 2025-12-04 | — | — | US | disclosed |
| EP-4631507-A2 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | Voronoi Inc. (KR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4619403-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | Voronoi, Inc. (KR) | 2025-09-24 | — | — | EP | disclosed |
| EP-3943491-B1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC (KR) | 2025-06-18 | — | — | EP | disclosed |
| US-12157730-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | VORONOI INC. (KR) | 2024-12-03 | — | — | US | disclosed |
| US-12152021-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | VORONOI INC. (KR) | 2024-11-26 | — | — | US | disclosed |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| WO-2020190119-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | 주식회사 보로노이 | 2020-09-24 | — | — | WO | disclosed |
| WO-2020190119-A1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | 주식회사 보로노이 | 2020-09-24 | — | — | WO | disclosed |
| US-7687529-B2 | Substituted propylamine derivatives and methods of their use | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7601744-B2 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1934193-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | Wyeth a Corporation of the State of Delaware (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934178-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007041258-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041257-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | TPH1, HTR1A, HTR5A | CES2 1554/4885CES1 909/4885GRIN2B 589/4885 |
| US-12157730-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | ERBB4, ERBB2, EGFR | CES2 3680/4885CES1 3409/4885GRIN2B 3037/4885 |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CES2 2857/4885CES1 3727/4885GRIN2B 2374/4885 |
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CES2 2512/4885CES1 3354/4885GRIN2B 2002/4885 |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | GLS, SLC6A4, SLC6A3 | CES2 606/4885CES1 1387/4885GRIN2B 1074/4885 |
| US-12152021-B2 | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | ERBB4, ERBB2, EGFR | CES2 3680/4885CES1 3409/4885GRIN2B 3037/4885 |
| US-20240317730-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CES2 2857/4885CES1 3727/4885GRIN2B 2374/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CES2 1116/4885CES1 706/4885GRIN2B 2686/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CES2 1186/4885CES1 807/4885GRIN2B 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.